A personalised vaccine against melanoma can more than double the survival
rate for patients with the advanced form of this skin cancer. Doctors at
Jefferson Medical College in Philadelphia create customised vaccines from
patients’ own cancer cells by inactivating them and altering their surface
proteins with dinitrophenol. Five-year survival rates in 214 patients with
advanced disease increased from around 20 per cent to 50 per cent and a
randomised phase III trial of 400 patients across the US is planned.
To continue reading, today with our introductory offers
Advertisement
More from New Scientist
Explore the latest news, articles and features
Popular articles
Trending New Scientist articles
1
Where, when and how to watch the 2026 solar eclipse
2
Our verdict on The Selfish Gene: An unpopular piece of popular science
3
If you aren't terrified by this heatwave, you should be
4
We鈥檝e uncovered a master gene that switches on human development
5
How menopause radically changes the brain 鈥 and what happens after
6
Parenting may permanently improve brain health for mums and dads
7
Woman with Alzheimer's starts conversing again after taking psilocybin
8
A quantum state that lasts forever may finally be within our grasp
9
You should turn off fans when it's too hot 鈥 but how hot is too hot?
10
Can prebiotics, probiotics or postbiotics help your ageing microbiome?
